1. Home
  2. REGN vs LMT Comparison

REGN vs LMT Comparison

Compare REGN & LMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • LMT
  • Stock Information
  • Founded
  • REGN 1988
  • LMT 1912
  • Country
  • REGN United States
  • LMT United States
  • Employees
  • REGN N/A
  • LMT N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • LMT Military/Government/Technical
  • Sector
  • REGN Health Care
  • LMT Industrials
  • Exchange
  • REGN Nasdaq
  • LMT Nasdaq
  • Market Cap
  • REGN 110.0B
  • LMT 116.2B
  • IPO Year
  • REGN 1991
  • LMT N/A
  • Fundamental
  • Price
  • REGN $681.58
  • LMT $490.37
  • Analyst Decision
  • REGN Buy
  • LMT Buy
  • Analyst Count
  • REGN 25
  • LMT 12
  • Target Price
  • REGN $1,024.28
  • LMT $588.25
  • AVG Volume (30 Days)
  • REGN 857.0K
  • LMT 1.2M
  • Earning Date
  • REGN 02-04-2025
  • LMT 01-28-2025
  • Dividend Yield
  • REGN N/A
  • LMT 2.69%
  • EPS Growth
  • REGN 15.31
  • LMT 0.98
  • EPS
  • REGN 40.43
  • LMT 27.67
  • Revenue
  • REGN $13,847,100,000.00
  • LMT $71,295,000,000.00
  • Revenue This Year
  • REGN $10.24
  • LMT $6.49
  • Revenue Next Year
  • REGN $4.30
  • LMT $3.88
  • P/E Ratio
  • REGN $16.86
  • LMT $17.72
  • Revenue Growth
  • REGN 5.72
  • LMT 5.33
  • 52 Week Low
  • REGN $666.25
  • LMT $413.92
  • 52 Week High
  • REGN $1,211.20
  • LMT $618.95
  • Technical
  • Relative Strength Index (RSI)
  • REGN 36.27
  • LMT 49.80
  • Support Level
  • REGN $666.25
  • LMT $461.24
  • Resistance Level
  • REGN $743.28
  • LMT $487.76
  • Average True Range (ATR)
  • REGN 19.76
  • LMT 7.86
  • MACD
  • REGN 0.45
  • LMT 3.49
  • Stochastic Oscillator
  • REGN 19.90
  • LMT 90.58

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

About LMT Lockheed Martin Corporation

Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Lockheed's largest segment is aeronautics, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.

Share on Social Networks: